FDA CBER Regulates HCT/Ps and Cell Gene Therapy Products Under 21 CFR Parts 1270 and 1271

For QA directors and regulatory affairs leads moving into advanced therapy manufacturing, CBER's dual-track framework under 21 CFR Parts 1270 and 1271 defines the compliance baseline before a single batch is released. The Center for Biologics Evaluation and Research draws a regulatory boundary between conventional HCT/Ps and the broader cell and gene therapy product categories, a distinction that carries direct consequences for GMP program design, donor eligibility protocols, and facility registration obligations.

Human cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient are classified as HCT/Ps. CBER's jurisdiction under this framework covers a wide material range: bone, skin, corneas, ligaments, tendons, dura mater, heart valves, and hematopoietic stem and progenitor cells derived from both peripheral and cord blood, as well as oocytes and semen. Each product type carries specific donor screening, testing, and processing requirements under Part 1271, and manufacturers must map their operations against those requirements at the process validation stage.

Separately, CBER regulates cellular therapy products, including cellular immunotherapies, cancer vaccines, and autologous and allogeneic cell preparations, alongside human gene therapy products and certain related devices. Gene therapy, as defined by CBER, encompasses interventions that modify or manipulate gene expression or alter the biological properties of living cells for therapeutic use. For manufacturers operating in this space, the regulatory pathway diverges meaningfully from conventional biologics: product characterisation expectations, comparability protocols, and lot release criteria reflect the complexity and variability inherent to living-cell starting materials.

For QA leads entering the ATMP space, the practical read is that Part 1271 compliance is not a subset of standard 21 CFR Part 211 GMP, it is a parallel framework with its own registration, listing, and current good tissue practice (cGTP) requirements. Facilities manufacturing products that meet the criteria for both HCT/P classification and drug or biological product regulation face layered obligations, and the risk of misclassification at the IND or BLA stage carries significant remediation cost. Early-stage compliance mapping against both frameworks is standard practice for sponsors entering CBER's review queue.

CBER's most recent published assessment under the Tissues and Advanced Therapeutics programme addresses immunoglobulin utilisation and shortage, dated February 2022, signalling that post-market surveillance and supply continuity remain active oversight priorities alongside pre-market regulatory activity.

Manufacturers building or auditing ATMP programmes should treat the Part 1270/1271 framework as a foundational compliance checkpoint, with product classification confirmed before process validation protocols are locked.

Source: FDA CBER via What's New Vaccines Blood Biologics RSS Feed, 22 June 2026.